PHARMACEUTICAL 2021

Phathom Pharmaceuticals Inc
Rank 201 of 394



PHARMACEUTICAL 2021

Phathom Pharmaceuticals Inc
Rank 201 of 394

The relative strengths and weaknesses of Phathom Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Phathom Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points.The greatest weakness of Phathom Pharmaceuticals Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 267%, being 11% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	291,368
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	55,524
Liabilities, Non-Current	45,316
Other Assets	2,757
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-3,403
Other Revenues	0
Property and Equipment	986
Research and Development	98,148
Selling, General and Administrative Expense	27,517

Output Variable	Value in 1000 USD
Assets	295,111
Liabilities	100,840
Expenses	125,665
Revenues	0
Stockholders Equity	194,271
Net Income	-129,068
Comprehensive Net Income	-129,068
BaseVar	262,510
ECR before LimitedLiability	149%
Economic Capital Ratio	267%